Long-Term Follow-Up of MonumenTAL-1

Opinion
Video

Larysa J. Sanchez, MD, discusses recent efficacy data presented at EHA 2024 from the long-term follow-up results of the phase 1/2 MonumenTAL-1 study investigating talquetamab in relapsed/refractory multiple myeloma.

Video content above is prompted by the following:

  • Please discuss the efficacy data, focusing on PFS and DOR, presented at EHA 2024 on the long-term follow-up results of the phase 1/2 MonumenTAL-1 study of talquetamab in patients with RRMM.
    • What factors might contribute to the longer DOR with Q2W dosing compared to QW dosing in patients naive to prior TCR?

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Subscribe Now!
Recent Videos
“If you have a [patient in the] fourth or fifth line, [JNJ-5322] could be a valid drug of choice,” said Rakesh Popat, BSc, MBBS, MRCP, FRCPath, PhD.
Earlier treatment with daratumumab may be better tolerated for patients with pretreated MRD-negative multiple myeloma.
The trispecific antibody JNJ-5322 demonstrated superior efficacy vs approved agents in multiple myeloma in results shared at the 2025 EHA Congress.
The dual high-affinity binding observed with ISB 2001 may avoid resistance mechanisms reported with other BCMA-targeted therapies.
4 experts are featured in this series.
4 experts are featured in this series.
4 experts are featured in this series.
4 experts are featured in this series.
4 experts are featured in this series.
4 experts are featured in this series.
Related Content
Phase 3 DREAMM-7 and DREAMM-8 trial results showed that combinations with belantamab mafodotin showed superior efficacy vs standard of care in the disease.

Belantamab Mafodotin Combos Receive EU Approval for R/R Multiple Myeloma

Roman Fabbricatore
July 24th 2025
Article

Phase 3 DREAMM-7 and DREAMM-8 trial results showed that combinations with belantamab mafodotin showed superior efficacy vs standard of care in the disease.

Samantha Shenoy, NP, MSN, discusses how her role plays a vital part in patient care for those receiving talquetamab for multiple myeloma.

Mitigating AEs and Protecting QOL Following Talquetamab in Multiple Myeloma

Samantha Shenoy, NP, MSN
October 14th 2024
Podcast

Samantha Shenoy, NP, MSN, discusses how her role plays a vital part in patient care for those receiving talquetamab for multiple myeloma.

ODAC Votes Against 2 Belantamab Mafodotin Combinations in Multiple Myeloma

ODAC Votes Against 2 Belantamab Mafodotin Combinations in Multiple Myeloma

Roman Fabbricatore
July 17th 2025
Article

ODAC voted against the favorability of the agent in combination with dexamethasone and pomalidomide or bortezomib in multiple myeloma.

James R. Berenson, MD, describes ongoing efforts to evaluate treatment with JAK inhibitors like ruxolitinib among patients with multiple myeloma.

Exploring the Potential Role of JAK Inhibitors in Multiple Myeloma

James R. Berenson, MD, FACP
September 30th 2024
Podcast

James R. Berenson, MD, describes ongoing efforts to evaluate treatment with JAK inhibitors like ruxolitinib among patients with multiple myeloma.

Treatment with ISB 2001 demonstrated robust responses across difficult-to-treat multiple myeloma subgroups in the phase 1 TRIgnite-1 study.

Novel Trispecific Antibody May Offer “Renewed Hope” in R/R Multiple Myeloma

Russ Conroy
July 9th 2025
Article

Treatment with ISB 2001 demonstrated robust responses across difficult-to-treat multiple myeloma subgroups in the phase 1 TRIgnite-1 study.

Longer follow-up from the phase 3 MIDAS trial may be necessary to evaluate progression-free survival and overall survival.

ASCT Shows No Significant MRD Difference vs Isa-KRd in Multiple Myeloma

Russ Conroy
July 9th 2025
Article

Longer follow-up from the phase 3 MIDAS trial may be necessary to evaluate progression-free survival and overall survival.